Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

NCT01736943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG: Bortezomib
DRUG: Doxil

Sponsor

Joseph Tuscano

Collaborators

[object Object]